Skip to main content
ConductScienceScienceDex
NIH funding notice RFA-AT-23-002

HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required)

Closed on November 21, 2022.

Posted
July 13, 2022
Close date
November 21, 2022
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $819,155 in first-year total cost, median $819,155.

Most frequent study sections

  1. Special Emphasis Panel[ZAT1 SN (10)]1

Most frequent institutions

  1. UNIVERSITY OF PITTSBURGH AT PITTSBURGH1
Competing awards under RFA-AT-23-002 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2023Peer suppoRt for adolescents and Emerging adults with Sickle cell pain: promoting ENgagement in Cognitive behavioral thErapy1UG3HL165839-01A1COLVIN, ALICIAJONASSAINT, CHARLES RICHARDRADOVIC-STAKIC, ANAUNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA$819,155ZAT1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

Start your CVHow the NIH biosketch works
RFA-AT-23-002: HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required) | ScienceDex | ConductScience